Inhibition of tissue factor pathway inhibitor increases the sensitivity of thrombin generation assay to procoagulant microvesicles

Blood Coagulation and Fibrinolysis

Volumn 24, Issue 5, 2013, Pages 567-572

  Gheldof, Damien ^a,b   Mullier, François ^a   Chatelain, Bernard ^a   Dogné, Jean Michel ^b   Chatelain, Christian ^a  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^b UNIVERSITY OF NAMUR   (Belgium)

Author keywords

Cancer; microvesicles; thrombin generation assay; thrombosis; tissue factor

Indexed keywords

MONOCLONAL ANTIBODY; PROCOAGULANT; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; BLOOD LEVEL; CELL CULTURE; CONTROLLED STUDY; DILUTION; ENZYME ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SUPERNATANT; THROMBIN GENERATION ASSAY;

ANTIBODIES, MONOCLONAL; BLOOD COAGULATION; BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOPLASMIC VESICLES; HUMANS; LIPOPROTEINS; PLASMA; SENSITIVITY AND SPECIFICITY; THROMBIN; THROMBOPLASTIN;

EID: 84879925842     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328360a56e     Document Type: Article

References (21)

1. Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J, et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost 2008; 6:1517-1524.
2. Debaugnies F, Azerad MA, Noubouossie D, Rozen L, Hemker HC, Corazza F, et al. Evaluation of the procoagulant activity in the plasma of cancer patientsusingathrombingenerationassay. Thromb Res 2010; 126:531-535.
3. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl JMed 2008; 359:938-949.
4. Mackman N. Role oftissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004; 24:1015-1022.
5. Zwicker JI.Tissuefactor-bearing microparticlesand cancer. Semin Thromb Hemost 2008; 34:195-198.
6. Wang JG, Geddings JE, Aleman MM, Cardenas JC, Chantrathammachart P, Williams JC, et al. Tumor-derived tissuefactoractivates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood 2012; 119:5543-5552.
7. Key NS, Mackman N. Tissue factor and its measurement in whole blood, plasma, and microparticles. Semin Thromb Hemost 2010; 36:865-875.
8. Yuana Y, Bertina RM, Osanto S. Preanalytical and analytical issues in the analysis of blood microparticles. Thromb Haemost 2011; 105:396-408.
9. Dargaud Y, Luddington R, Gray E, Negrier C, Lecompte T, Petros S, et al. Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study. Br J Haematol 2007; 139:303-309.
10. Yamamuro M, Wada H, Kumeda K, Inoue A, Tsuji I, Nakasaki T, et al. Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation. Blood Coagul Fibrinolysis 1998; 9:491-497.
11. Shimura M, Wada H, Wakita Y, Nakase T, Hiyoyama K, Nagaya S, et al. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 1996;52:165-170.
12. Robert S, Ghiotto J, Pirotte B, David JL, Masereel B, Pochet L, et al. Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs? Pharmacol Res 2009; 59:160-166.
13. Khorana AA, Streiff MB, Farge D, Mandala M, Debourdeau P, Cajfinger F, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009; 27:4919-4926.
14. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111:4902-4907.
15. Manly DA, Wang J, Glover SL, Kasthuri R, Liebman HA, Key NS, et al. Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb Res 2010; 125:511-512.
16. Owens AP 3rd, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res 2011; 108:1284-1297.
17. Zwicker JI. Predictivevalue oftissuefactorbearing microparticles in cancer associated thrombosis. Thromb Res 2010; 125 (Suppl 2):S89-S91.
18. Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15:6830-6840.
19. Menapace LA, Khorana AA. The role of thromboprophylaxis in cancer patients: emerging data. Curr Opin Hematol 2010; 17:450-456.
20. Gorczyca ME, Nair SC, Jilma B, Priya S, Male C, Reitter S, et al. Inhibition of tissue factor pathway inhibitor (TFPI) by the aptamer BAX499 improves clotting of hemophiliac blood and plasma. J Thromb Haemost 2012; 10:1581-1590.
21. Duchemin J, Pan-Petesch B, Arnaud B, Blouch MT, Abgrall JF. Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma. Thromb Haemost 2008; 99:767-773.